Semax 10mg
Cognitive
$99
Russian-developed ACTH analog that upregulates BDNF, enhances dopaminergic and serotonergic tone, and improves memory, focus, and neuroprotection.
Overview
Semax is a heptapeptide analog of ACTH(4-10) developed at the Institute of Molecular Genetics in Moscow and approved in Russia for stroke, cognitive decline, and optic nerve disease. It dramatically upregulates BDNF (brain-derived neurotrophic factor) and its receptor TrkB, enhancing synaptic plasticity and neuronal survival. It also modulates dopaminergic, serotonergic, and cholinergic systems for acute cognitive enhancement.
Lab Results — 10mg
Every batch is independently tested. Results below are from the Certificate of Analysis for the 10mg batch.
Scientific Details
Molecular Formula
C₃₇H₅₁N₉O₁₀S
Molecular Weight
813.9 g/mol
Form
Lyophilized peptide powder
Solubility
Soluble in sterile water or saline
Dosage Range
200–900mcg daily intranasal (research context)
Plasma Half-Life
~20 minutes (plasma); prolonged CNS effects
Bioavailability
~90% intranasal
Resources
Key peer-reviewed studies supporting the efficacy and safety of this compound.
Semax and BDNF upregulation in rat brain
Shadrina M.I. et al. — Journal of Molecular Neuroscience (2010)
Key FindingSemax administration produced a 1.6-fold increase in BDNF mRNA expression in the rat hippocampus within 24 hours.
Neuroprotective effects of Semax in ischemic stroke
Miasoedov N.F. et al. — Zhurnal Nevrologii i Psikhiatrii (1999)
Key FindingSemax reduced infarct volume and improved neurological outcomes in a randomized controlled trial of acute ischemic stroke patients.
ACTH(4-10) analogs and cognitive performance
De Wied D. — Progress in Brain Research (1990)
Key FindingACTH fragment analogs improved attention, memory consolidation, and cognitive flexibility in both animal models and human trials.